WO2007100795A3 - Combinations comprising a histone deacetylase inhibiting agent and a nuclear hormone receptor ligand for treating cardiovascular conditions - Google Patents

Combinations comprising a histone deacetylase inhibiting agent and a nuclear hormone receptor ligand for treating cardiovascular conditions Download PDF

Info

Publication number
WO2007100795A3
WO2007100795A3 PCT/US2007/005019 US2007005019W WO2007100795A3 WO 2007100795 A3 WO2007100795 A3 WO 2007100795A3 US 2007005019 W US2007005019 W US 2007005019W WO 2007100795 A3 WO2007100795 A3 WO 2007100795A3
Authority
WO
WIPO (PCT)
Prior art keywords
hormone receptor
histone deacetylase
receptor ligand
combinations
nuclear hormone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/005019
Other languages
French (fr)
Other versions
WO2007100795A2 (en
Inventor
Craig F Plato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Colorado Inc
Original Assignee
Gilead Colorado Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Colorado Inc filed Critical Gilead Colorado Inc
Priority to EP07751753A priority Critical patent/EP1996233A2/en
Priority to CA002644933A priority patent/CA2644933A1/en
Publication of WO2007100795A2 publication Critical patent/WO2007100795A2/en
Priority to US12/198,609 priority patent/US20090076021A1/en
Anticipated expiration legal-status Critical
Publication of WO2007100795A3 publication Critical patent/WO2007100795A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A therapeutic combination, useful in a co-therapy method for improving cardiovascular performance and/or treating cardiovascular diseases, is provided comprising a first agent and a second agent, wherein the first agent comprises a histone deacetylase inhibiting agent and the second agent comprises at least one nuclear hormone receptor ligand.
PCT/US2007/005019 2006-02-27 2007-02-26 Combinations comprising a histone deacetylase inhibiting agent and a nuclear hormone receptor ligand for treating cardiovascular conditions Ceased WO2007100795A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP07751753A EP1996233A2 (en) 2006-02-27 2007-02-26 Combinations comprising a histone deacetylase inhibiting agent and a nuclear hormone receptor ligand for treating cardiovascular conditions
CA002644933A CA2644933A1 (en) 2006-02-27 2007-02-26 Combinations comprising a histone deacetylase inhibiting agent and a nuclear hormone receptor ligand for treating cardiovascular conditions
US12/198,609 US20090076021A1 (en) 2006-02-27 2008-08-26 Therapeutic combinations and methods for cardiovascular improvement and treating cardiovascular disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77738706P 2006-02-27 2006-02-27
US60/777,387 2006-02-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/198,609 Continuation US20090076021A1 (en) 2006-02-27 2008-08-26 Therapeutic combinations and methods for cardiovascular improvement and treating cardiovascular disease

Publications (2)

Publication Number Publication Date
WO2007100795A2 WO2007100795A2 (en) 2007-09-07
WO2007100795A3 true WO2007100795A3 (en) 2008-12-18

Family

ID=38255809

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/005019 Ceased WO2007100795A2 (en) 2006-02-27 2007-02-26 Combinations comprising a histone deacetylase inhibiting agent and a nuclear hormone receptor ligand for treating cardiovascular conditions

Country Status (4)

Country Link
US (1) US20090076021A1 (en)
EP (1) EP1996233A2 (en)
CA (1) CA2644933A1 (en)
WO (1) WO2007100795A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207950A1 (en) * 2005-12-21 2007-09-06 Duke University Methods and compositions for regulating HDAC6 activity
US7737175B2 (en) 2007-06-01 2010-06-15 Duke University Methods and compositions for regulating HDAC4 activity
WO2009002534A1 (en) * 2007-06-26 2008-12-31 Gilead Colorado, Inc. Imidazopyridinyl thiazolyl histone deacetylase inhibitors
CA2728228A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
WO2010009139A2 (en) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Imidazolyl pyrimidine inhibitor compounds
NZ602832A (en) 2008-07-14 2014-04-30 Gilead Sciences Inc Fused heterocyclic hdac inhibitor compounds
MX2011001090A (en) 2008-07-28 2011-03-15 Gilead Sciences Inc Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds.
ES2463826T3 (en) 2009-06-08 2014-05-29 Gilead Sciences, Inc. HDAC inhibitor compounds of cycloalkylcarbamate benzamide aniline
WO2010144371A1 (en) 2009-06-08 2010-12-16 Gilead Colorado, Inc. Alkanoylamino benzamide aniline hdac inihibitor compounds
WO2015160696A1 (en) * 2014-04-14 2015-10-22 Yale University Compositions and methods of inhibiting histone deacetylases
AU2015287947B2 (en) * 2014-07-09 2017-11-23 Darlene E. MCCORD Compositions for anti-inflammatory, antioxidant effects and improved respiratory function by specific histone deacetylase inhibition
IT201900005762A1 (en) * 2019-04-16 2020-10-16 Alberto Chiarugi THERAPY OF NEUROVASCULAR DISORDERS

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048825A1 (en) * 1997-05-01 1998-11-05 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
WO1999023885A1 (en) * 1997-11-10 1999-05-20 The Salk Institute For Biological Studies Methods for the use of inhibitors of co-repressors for the treatment of neoplastic diseases
WO2001049290A1 (en) * 2000-01-04 2001-07-12 The Johns Hopkins University Methods and reagents for facilitating transcription
WO2002055688A2 (en) * 2001-01-10 2002-07-18 Us Gov Health & Human Serv Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
WO2005087206A2 (en) * 2004-03-10 2005-09-22 The University Of Birmingham Cancer therapy comprising a nuclear receptor ligand and a hdac inhibitor
WO2006005941A1 (en) * 2004-07-12 2006-01-19 Istituto Di Ricerche Di Biologia Molecolare P Angeletti S.P.A. Amide derivatives as inhibitors of histone deacetylase
WO2006127977A1 (en) * 2005-05-24 2006-11-30 The Johns Hopkins University Fatty acid carbohydrate hybrid molecules as therapeutic agents and methods thereof
WO2007067994A1 (en) * 2005-12-09 2007-06-14 Kalypsys, Inc. Inhibitors of histone deacetylase for the treatment of disease
WO2008058287A1 (en) * 2006-11-10 2008-05-15 Syndax Pharmaceuticals, Inc. COMBINATION OF ERα+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040006011A1 (en) * 1996-07-12 2004-01-08 Gour Barbara J. Peptidomimetic modulators of cell adhesion
US20020168761A1 (en) * 2000-01-24 2002-11-14 Gour Barbara J. Peptidomimetic modulators of cell adhesion
US5760246A (en) * 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
US6403588B1 (en) * 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
US20020177594A1 (en) * 2001-03-14 2002-11-28 Curtin Michael L. Inhibitors of histone deacetylase
US7868204B2 (en) * 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
US7320989B2 (en) * 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
US20050187266A1 (en) * 2003-04-15 2005-08-25 Pfizer Inc Alpha substituted carboxylic acids
US20050234066A1 (en) * 2004-04-15 2005-10-20 Agouron Pharmaceuticals, Inc. Alpha substituted carboxylic acids
US20070093492A1 (en) * 2004-03-09 2007-04-26 Weir-Torn Jiaang Pyrrolidine derivatives
US7253204B2 (en) * 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
CN101223161A (en) * 2005-06-24 2008-07-16 健亚生物科技公司 Heteroaryl derivatives for the treatment of viral infections

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048825A1 (en) * 1997-05-01 1998-11-05 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
WO1999023885A1 (en) * 1997-11-10 1999-05-20 The Salk Institute For Biological Studies Methods for the use of inhibitors of co-repressors for the treatment of neoplastic diseases
WO2001049290A1 (en) * 2000-01-04 2001-07-12 The Johns Hopkins University Methods and reagents for facilitating transcription
WO2002055688A2 (en) * 2001-01-10 2002-07-18 Us Gov Health & Human Serv Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
WO2005087206A2 (en) * 2004-03-10 2005-09-22 The University Of Birmingham Cancer therapy comprising a nuclear receptor ligand and a hdac inhibitor
WO2006005941A1 (en) * 2004-07-12 2006-01-19 Istituto Di Ricerche Di Biologia Molecolare P Angeletti S.P.A. Amide derivatives as inhibitors of histone deacetylase
WO2006127977A1 (en) * 2005-05-24 2006-11-30 The Johns Hopkins University Fatty acid carbohydrate hybrid molecules as therapeutic agents and methods thereof
WO2007067994A1 (en) * 2005-12-09 2007-06-14 Kalypsys, Inc. Inhibitors of histone deacetylase for the treatment of disease
WO2008058287A1 (en) * 2006-11-10 2008-05-15 Syndax Pharmaceuticals, Inc. COMBINATION OF ERα+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KEEN J C ET AL: "A novel histone deacetylase inhibitor, Scriptaid, enhances expression of functional estrogen receptor [alpha] (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine", BREAST CANCER RESEARCH AND TREATMENT 2003 UNITED STATES, vol. 81, no. 3, 2003, pages 177 - 186, XP008081645, ISSN: 0167-6806 *
KHALIL R A: "Sex hormones as potential modulators of vascular function in hypertension", HYPERTENSION 200508 US, vol. 46, no. 2, August 2005 (2005-08-01), pages 249 - 254, XP008097850, ISSN: 0194-911X *
SATO Y ET AL: "Thyroid hormone targets matrix Gla protein gene associated with vascular smooth muscle calcification", CIRCULATION RESEARCH 20050916 US, vol. 97, no. 6, 16 September 2005 (2005-09-16), pages 550 - 557, XP008097841, ISSN: 0009-7330 *
WU S -Y ET AL: "Alternate pathways of thyroid hormone metabolism", THYROID 200508 US, vol. 15, no. 8, August 2005 (2005-08-01), pages 943 - 958, XP008097856, ISSN: 1050-7256 *

Also Published As

Publication number Publication date
WO2007100795A2 (en) 2007-09-07
US20090076021A1 (en) 2009-03-19
EP1996233A2 (en) 2008-12-03
CA2644933A1 (en) 2007-09-07

Similar Documents

Publication Publication Date Title
WO2007100795A3 (en) Combinations comprising a histone deacetylase inhibiting agent and a nuclear hormone receptor ligand for treating cardiovascular conditions
WO2008131376A3 (en) Methods and compositions for treating and monitoring treatment of il-13-associated disorders
PT1949285T (en) Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
WO2008067387A3 (en) Estrogen/ serm and estrogen/ progestin bi-layer tablets
EP2013165A4 (en) Diphenylazetidinone derivates possessing cholesterol absor tion inhibitor activit.
EP2024018A4 (en) Portable assemblies, systems, and methods for providing functional or therapeutic neurostimulation
WO2008036144A3 (en) Nanoshells on polymers
PL1830928T3 (en) System, in particular, fire-fighting system with valves
WO2007100895A3 (en) Cancer treatment with gamma-secretase inhibitors
IL191538A0 (en) Method for diagnosing, prognosing and treating glioma
EP1850484A4 (en) Basic matrix based on irregular ldcp, codec and generation method thereof
PT2145276T (en) Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
EP2011552A4 (en) Exercise management system, exercise management method, and exercise management program
EP2128772A4 (en) Message hub, program, and method
WO2006137106A3 (en) Method for the potentiation of opioid analgesics effects on pain
EP2081337A4 (en) System, method and devices for achieving the multimedia session continuity
WO2009129147A3 (en) Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation
IL174033A0 (en) Multi-system therapy for diabetes, the metabolic syndrome and obesity comprising a hypoglycemic agent
PT1832816T (en) Hydraulic device, hydraulic appliance, hydraulic system and method for its use
EP1784150A4 (en) Transdermal antiemesis delivery system, method and composition therefor
WO2006063332A3 (en) Markers for metabolic syndrome obesity and insulin resistance
IL185377A0 (en) Method for a medicinal combination treatment, and medicament combinations suitable therefor
ZA200609895B (en) Methods for treating a mammal before, during and after cardiac arrest
WO2006042192A3 (en) Relevance of achieved levels of markers of systemic inflammation following treatment
WO2007147868A3 (en) Prevention of muscle atrophy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2644933

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007751753

Country of ref document: EP